1. Home
  2. UTF vs VERA Comparison

UTF vs VERA Comparison

Compare UTF & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cohen & Steers Infrastructure Fund Inc

UTF

Cohen & Steers Infrastructure Fund Inc

HOLD

Current Price

$26.98

Market Cap

2.8B

Sector

Finance

ML Signal

HOLD

Logo Vera Therapeutics Inc.

VERA

Vera Therapeutics Inc.

HOLD

Current Price

$36.04

Market Cap

3.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
UTF
VERA
Founded
N/A
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.8B
3.2B
IPO Year
2004
2021

Fundamental Metrics

Financial Performance
Metric
UTF
VERA
Price
$26.98
$36.04
Analyst Decision
Strong Buy
Analyst Count
0
10
Target Price
N/A
$81.30
AVG Volume (30 Days)
295.3K
1.1M
Earning Date
01-01-0001
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$472.48
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$23.42
$18.76
52 Week High
$27.35
$56.05

Technical Indicators

Market Signals
Indicator
UTF
VERA
Relative Strength Index (RSI) 60.91 39.02
Support Level $26.65 $22.10
Resistance Level $27.17 $42.77
Average True Range (ATR) 0.34 1.82
MACD 0.04 -0.23
Stochastic Oscillator 74.07 22.73

Price Performance

Historical Comparison
UTF
VERA

About UTF Cohen & Steers Infrastructure Fund Inc

Cohen & Steers Infrastructure Fund Inc is a diversified, closed-end management investment company. Its primary investment objective is total return with an emphasis on income. Under normal market conditions, the fund invests the majority of its managed assets in securities issued by infrastructure companies, which consist of utilities, pipelines, toll roads, airports, railroads, ports, telecommunications companies, and other infrastructure companies.

About VERA Vera Therapeutics Inc.

Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.

Share on Social Networks: